Immuneering’s Pancreatic Cancer Drug Doubles Survival to 17.3 Months — Stock Falls Anyway
Immuneering's drug combo doubled pancreatic cancer survival (17.3 vs 8.5 months) and looked safe, but shares dropped.
/ 4 items
#IMRX↓
Immuneering's Pancreatic Cancer Data Fails to Impress: Stock Plunges 23% Despite Survival Claims
Immuneering (IMRX) reports 64% survival rate for Atebimetinib in pancreatic cancer trial, but shares plunge 23% as investors remain unconvinced about cross-trial comparisons and competitive threats.
Biotech Upgrades: FATE, IMCR, IMRX Get Bullish Analyst Calls
Analysts upgrade Fate Therapeutics to Buy and initiate bullish coverage on Immunocore and Immuneering, citing promising drug trials and strong revenue potential in lupus and cancer treatments.
Immuneering Atebimetinib Demonstrates Exceptional Pancreatic Cancer Survival
New pancreatic cancer drug (atebimetinib + chemo) shows "extraordinary" results: 86% overall survival (OS) at 9 months, far exceeding the 47% standard of care. Pivotal trials planned for late 2025.